2. Academic Validation
  3. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma

Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma

  • Biomark Res. 2019 Apr 11;7:9. doi: 10.1186/s40364-019-0160-4.
Amandeep Aujla 1,  Ravijot Aujla 2,  Delong Liu 1 3
Affiliations

Affiliations

  • 1 1Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595 USA.
  • 2 2Punjab Institute of Medical Sciences, Jalandhar, Punjab 144006 India.
  • 3 3Department of Oncology, The First affiliated hospital of Zhengzhou University, Zhengzhou, China.
PMID: 31011424 DOI: 10.1186/s40364-019-0160-4
Abstract

B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) frequently express CD19, CD20 and CD22 on the cell surfaces. Immunotherapeutic agents including Antibodies and chimeric antigen receptor T cells are widely studied in clinical trials. Several antibody-drug conjugates (ADC) have been approved for clinical use (gemtuzumab ozogamicin in acute myeloid leukemia and brentuximab vedotin in Hodgkin lymphoma as well as CD30+ anaplastic large cell lymphoma). Inotuzumab ozogamicin (INO), a CD22 antibody conjugated with calicheamicin is one of the newest ADCs. INO has been approved for treatment of relapsed /refractory B cell precursor ALL. Multiple ongoing trials are evaluating its role in the relapsed /refractory B cell NHL. This review summarized recent development in INO applications for ALL and NHL.

Keywords

ADC; Acute lymphoblastic leukemia; Antibody-drug conjugate; CD22; Inotuzumab ozogamicin; Non-Hodgkin lymphoma.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z